ProQR Therapeutics (PRQR) | Stock Overview & Key Data
ProQR Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $2.28
High: $2.49
on September 4, 2025
52 Week Range
Low: $1.07
High: $4.62
on April 9, 2025
on October 17, 2024
All-Time High: $27.60 on March 16, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$241.2M
EPS
-0.47
P/E Ratio (TTM)
-7.25
Forward P/E
-4.79
P/B Ratio
3.54
PEG Ratio
-0.02
Div. Yield
N/A
ROE
-79.47%
Beta
0.427
Debt to Equity
25.17
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-308.15%
Profit Margin
-231.45%
Returns and Earnings
Return on Assets (TTM)
-20.47%
Return on Equity (TTM)
-79.47%
EBITDA
$-48.1M
Net Income (TTM)
$-46.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.16
Quarterly Revenue Growth (YoY)
-38.50%
Quarterly Earnings Growth (YoY)
-29.04%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| ProQR Therapeutics PRQR | 241.24M Micro-cap | 9.13% | 15.46% | 32.04% | 18.32% | -12.77% | 28.49% | 202.53% | -53.05% |
| Vertex VRTX | 102.81B Large-cap | 1.24% | -15.95% | -10.97% | -18.36% | -2.18% | -15.19% | 35.88% | 53.87% |
| Regeneron REGN | 61.25B Large-cap | -2.14% | -0.76% | 16.97% | -16.03% | -20.69% | -49.87% | -21.69% | 4.12% |
| Bright Minds DRUG | 245.98M Micro-cap | 3.10% | 23.91% | 59.53% | 36.36% | 6.91% | 3,562.50% | 459.87% | 64.30% |
| Atea Pharmaceuticals AVIR | 244.94M Micro-cap | -4.03% | -5.67% | 3.10% | 14.83% | -2.63% | -7.50% | -57.74% | -89.02% |
| Third Harmonic Bio THRD | 242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.85% | -51.27% | -53.82% | -70.11% | -70.11% |
Ownership & Short Interest
Insider Ownership
18.04%
Institutional Ownership
50.64%
Shares Short
358K
Short Ratio
1.50
Short % of Shares Outstanding
0.48%
Average 10-Day Volume
365K
Average 90-Day Volume
286K
Warning: Undefined variable $nickname in /usr/local/lsws/wordpress/wp-content/themes/egnitech-devyara/templates/stock-overview.php on line 329
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PRQR's 52-week high and low?
- In the last 52 weeks, ProQR Therapeutics reached a high of $4.62 (on October 17, 2024) and a low of $1.07 (on April 9, 2025).
- What is the market cap and P/E ratio for PRQR?
- Curious about ProQR Therapeutics's size and valuation? Its market capitalization stands at 241.24M. When it comes to valuation, the P/E ratio (trailing twelve months) is -7.25, and the forward P/E (looking ahead) is -4.79.
- Does PRQR pay dividends? If so, what's the yield?
- As for dividends, ProQR Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are ProQR Therapeutics's main competitors or similar companies to consider before investing?
When looking at ProQR Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX102.81B Healthcare Biotechnology -15.19% 35.88% Regeneron
REGN61.25B Healthcare Biotechnology -49.87% -21.69% Bright Minds
DRUG245.98M Healthcare Biotechnology 3,562.50% 459.87% Atea Pharmaceuticals
AVIR244.94M Healthcare Biotechnology -7.50% -57.74% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for ProQR Therapeutics N.V.? (e.g., ROE, Debt/Equity)
- To get a sense of ProQR Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -79.47%, the Debt to Equity ratio from the most recent quarter is 25.17, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for PRQR?
- Looking at ProQR Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $20M. Compared to the same quarter last year (YoY), quarterly revenue grew by -38.50%, and quarterly earnings saw a YoY growth of -29.04%.
- How much of PRQR stock is held by insiders and institutions?
- Wondering who owns ProQR Therapeutics stock? Company insiders (like executives and directors) hold about 18.04% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 50.64%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.